Melbourne technology firm, Rhinomed (ASX:RNO) today announced that CEO and Managing Director Mr. Michael Johnson will present a company update at the 8th Annual OneMed Forum on Monday, 12th January 2015 at 11.40 PST at the Marriott Marquis in San Francisco.
OTC Markets Group recently launched the OTCQX Composite Index (.OTCQX), OTCQX International Index (.OTCQXINT) and OTCQX U.S. Index (.OTCQXUS), to provide investors with a benchmark of the established, global and growth companies traded on the OTCQX marketplace.
Melbourne technology firm, Rhinomed (ASX:RNO) is pleased to announce that it has appointed sales and marketing brokerage firm Brand Solutions Australia to represent Mute in the Australian Pharmacy and Grocery channel.
Compumedics Limited (ASX:CMP) is pleased to announce it has executed a new export working capital guarantee facility with EFIC in conjunction with the ANZ Bank. This new facility will provide funding of up to USD$l.OM to enable the Company to continue to grow and develop its key export markets. The facility is complementary to Compumedics existing working capital facilities.
Melbourne technology firm, Rhinomed (ASX:RNO) is pleased to announce that it has received a Research and Development tax refund of $570,337.
Regenerative medicine company, Regeneus Ltd (ASX:RGS), announced today the granting by the Australian Patent Office of Australian patent number 2013203072. This Regeneus owned patent covers a method for freezing cells that maintains viability and functionality of the cells.
Melbourne bio-technology firm, Rhinomed (ASX:RNO) is pleased to announce the release of its newest device from its nasal respiratory technology stable of products, Mute(TM), a nasal breathing aid to alleviate snoring and improve sleep quality.
